Topical Finasteride Systemic Absorption: Pharmacokinetic Data
Medically reviewed by [Reviewer Name, MD] | Last reviewed: August 2026 | Editorial policy
The primary pharmacokinetic argument for topical over oral finasteride is that topical application limits how much drug enters systemic circulation — reducing systemic DHT suppression and potentially reducing systemic side effects. Here is what the published data show.
Key Pharmacokinetic Data
| Study | Formulation | Serum DHT Reduction | Oral 1 mg Comparison |
|---|---|---|---|
| Caserini et al. 2016 | Topical 0.25% spray (LADD) | ~16% | Oral 1 mg: ~72% |
| Piraccini et al. 2022 | Topical 0.25% spray (LADD) | ~15–25% | Oral 1 mg: ~70% |
| Scalp DHT reduction (Caserini) | Topical 0.25% | ~39% | Oral 1 mg: ~66% |
What Does This Mean Clinically?
- Topical finasteride 0.25% produces approximately 22% of the systemic DHT suppression of oral 1 mg — substantially lower systemic exposure
- Scalp DHT suppression is approximately 59% of oral at this concentration — suggesting meaningful local activity with reduced systemic effect
- Whether the reduced scalp DHT suppression translates to meaningfully lower hair regrowth vs. oral is not yet established in long-term head-to-head trials
- Formulation matters significantly — LADD (Liquid Atypical Drug Delivery) technology and different vehicles produce different skin permeation rates; data from one formulation should not be extrapolated to compounded preparations
See: Topical finasteride hub | Topical vs. oral comparison | Topical side effects | Clinical trials
Sources
- Caserini M, et al. “Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy male volunteers.” Int J Clin Pharmacol Ther. 2016;54(1):19–27.
- Piraccini BM, et al. “Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia.” J Eur Acad Dermatol Venereol. 2022;36(2):286–294.